As clinicians celebrated results of the PALOMA-2 study at ASCO Annual Meeting in 2016, Gabe S. Sonke, MD, PhD, had a question ...

Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients ...

Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Kailera Therapeutics launched with a four-drug pipeline aimed at the ...

CDK 4/6 inhibitors are a treatment for hormone receptorpositive (HR-positive), HER2-negative breast cancer that has spread to other parts of the body. They come as pills, and are often given with ...

Your doctor will check your blood at regular intervals during treatment. When you start taking these medications, your doctor may do blood tests once every two weeks. After the first couple of visits, ...